Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Durvalumab Maintenance in ES-SCLC
NCT07459634Phase 2Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Nov 2026; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07459634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459634.